Comparative Pharmacology
Head-to-head clinical analysis: INVEGA SUSTENNA versus SYLEVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA SUSTENNA versus SYLEVIA.
INVEGA SUSTENNA vs SYLEVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is an atypical antipsychotic that acts primarily as a central dopamine type 2 (D2) receptor antagonist and serotonin type 2A (5-HT2A) receptor antagonist. It also blocks α1- and α2-adrenergic receptors and H1 histamine receptors.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist, producing sedation, analgesia, and anxiolysis by reducing norepinephrine release in the locus coeruleus.
Initiate with 234 mg intramuscular injection on day 1, then 156 mg on day 8, both deltoid. Maintenance: 117 mg monthly (range 39-234 mg) via deltoid or gluteal injection. Dosing based on paliperidone palmitate.
Adults: 400 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life ranges from 25 to 49 days (mean ~38 days) for deltoid injection and 30 to 50 days (mean ~45 days) for gluteal injection, supporting monthly dosing.
Terminal elimination half-life is 27-33 hours in adults with normal renal function. Clinical context: Requires dose adjustment in renal impairment (creatinine clearance <30 mL/min reduces clearance by 50%).
Renal: approximately 59-80% as unchanged drug and metabolites, with about 1% unchanged; biliary/fecal: approximately 20-41% primarily as metabolites.
Renal excretion accounts for approximately 70% of the administered dose as unchanged drug, with biliary/fecal elimination contributing 20-30% (primarily as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic